Analysts Sees Synergies and Struggles in AngioDynamics' (ANGO) Latest Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AngioDynamics (ANGO) to Acquire Vortex Medical in $15M + Earnout Deal
October 8, 2012 4:14 PM EDTAngioDynamics, Inc. (NASDAQ: ANGO) announced today it has entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.
Based in Norwell, Massachusetts, Vortex is currently commercializing the AngioVac system, which includes the AngioVac Cannula and Circuit. These two disposable devices, when combined with other manufacturers' filters, pumps and return cannula, comprise an extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion... More
AngioDynamics, Inc. (ANGO) Tops Q1 EPS by 1c; Lowers FY13 EPS outlook
October 8, 2012 4:07 PM EDTAngioDynamics, Inc. (NASDAQ: ANGO) reported Q1 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $83.4 million versus the consensus estimate of $84.35 million.
AngioDynamics, Inc. sees FY2013 EPS of $0.40-0.42, versus the consensus of $0.50.
For earnings history... More
